SOOIL Dana-i

The Dana-i (SOOIL Development, distributed in the UK and EU by Advanced Therapeutics) is a tubed durable insulin pump — not a patch/tubeless device. Insulin runs from the pump body through a thin tube to a separate infusion set on the skin. What makes it notable is not its form factor but its openness: it is the delivery hardware behind the CE-marked Dana CamAPS FX hybrid closed loop and one of the primary supported pumps for AndroidAPS, the open-source automated insulin delivery (AID) app.¹²

Size, reservoir and wear. It is one of the smallest and lightest durable pumps in the world, about 86 g including the battery, and holds a 300-unit (3.0 mL) reservoir.³⁴ That reservoir lasts most people the standard ~3 days between set changes. It is IP68 water-resistant and runs on a single replaceable AAA battery that lasts roughly 2–3+ weeks even while looping — swapped in seconds, with no overnight charging.³⁴ It uses proprietary SOOIL infusion sets, reservoirs and cannulas.³

Occlusion detection and reliability. The pump has hardware alarms for occlusion, low reservoir, low battery and missed bolus.³ Its strongest reliability evidence is clinical: the randomized CREATE trial (New Zealand, 2022) paired a preproduction Dana-i with Dexcom G6 and AndroidAPS and raised time-in-range by 14 percentage points versus a sensor-augmented pump, with no diabetic ketoacidosis or severe hypoglycemia.⁵ A 24-week continuation phase (48 weeks total) confirmed the safety signal held over time, though most participants switched to a preproduction YpsoPump during that phase.⁶ In DIY use, intermittent Bluetooth connection losses are reported, though in most cases the intended insulin is still delivered.¹

CGMs, algorithms and DIY. Through CamAPS FX, the Dana-i closes the loop with Dexcom G6; CamAPS FX was the first CE-marked app-based hybrid closed loop, licensed from age 1 and up and in pregnancy.⁷⁸ Through AndroidAPS (supported from app version 3.0), it runs the open-source OpenAPS algorithm — the same DIY pathway validated in the CREATE trial and in earlier work on the closely related Dana RS pump.¹⁹

Phone bolusing. Bolusing is genuinely phone-first: the AnyDANA app (Android and iOS) gives full discrete remote control, and in a loop the bolus is delivered straight from the CamAPS FX or AndroidAPS phone app.³²

Access and cost by region. The Dana-i is CE-marked and available across the UK, EU and parts of Asia, including NHS/insurer-funded routes in the UK; it is not marketed in the US.²⁵ Where paid for privately rather than through public/insurer funding, the upfront pump and ongoing annual consumables represent a substantial out-of-pocket cost.¹⁰

What's coming. Diabeloop says DBLG2 is already available with Kaleido and is coming soon with Dana-i, but that is a European product update with no date.¹¹ It is not evidence of a US Dana-i launch. FDA clearance K251152 covers the DBLG2 algorithm as an interoperable automated glycemic controller; it does not clear Dana-i hardware.¹² Diabeloop's announced US integration is instead with Sequel's twiist, targeted for readiness by the end of 2026 and launch in 2027.¹³ No verified US Dana-i commitment or timeline remains.

References

1. AndroidAPS Documentation. DanaRS and Dana-i Pump. androidaps.readthedocs.io (accessed 2026). https://androidaps.readthedocs.io/en/latest/CompatiblePumps/DanaRS-Insulin-Pump.html ↩ ↩² ↩³

2. Advanced Therapeutics (UK) Ltd. Dana CamAPS FX. advancedtherapeutics.org.uk (accessed 2026). https://www.advancedtherapeutics.org.uk/dana-camaps-fx/ ↩ ↩² ↩³

3. SOOIL Development. Diabecare Dana-i Insulin Pump — product specifications. SOOIL (accessed 2026). https://www.sooil.com/eng/product/ ↩ ↩² ↩³ ↩⁴ ↩⁵

4. Advanced Therapeutics (UK) Ltd. The Dana i System. advancedtherapeutics.org.uk (accessed 2026). https://advancedtherapeutics.org.uk/shop/dana-diabecare-insulin-pump/dana-i-insulin-pump/ ↩ ↩²

5. Burnside MJ, Lewis DM, Crocket HR, et al. Open-Source Automated Insulin Delivery in Type 1 Diabetes. New England Journal of Medicine 387:869-881 (2022). PMID 36069869. https://doi.org/10.1056/NEJMoa2203913 ↩ ↩²

6. Burnside MJ, Lewis DM, Crocket HR, et al. Extended Use of an Open-Source Automated Insulin Delivery System: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial. Diabetes Technology & Therapeutics 25:250-259 (2023). PMID 36763345. https://doi.org/10.1089/dia.2022.0484 ↩

7. Dexcom. Dana CamAPS FX — Integrations and Partnerships. dexcom.com (accessed 2026). https://www.dexcom.com/en-gb/integrations-and-connectivity/insulin-pumps/dana-camaps-fx ↩

8. diaTribe. mylife CamAPS FX System: AID for All Ages. diatribe.org (accessed 2026). https://diatribe.org/diabetes-technology/mylife-camaps-fx-system-aid-all-ages ↩

9. Gawrecki A, Zozulinska-Ziolkiewicz D, Michalak MA, et al. Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. PLOS ONE 16:e0248965 (2021). PMID 33819289. https://doi.org/10.1371/journal.pone.0248965 ↩

10. Diabetes.co.uk. Cost of Insulin Pumps — Buying a Pump on the NHS or Privately. diabetes.co.uk (accessed 2026). https://www.diabetes.co.uk/insulin-pumps/buying-an-insulin-pump.html ↩

11. Diabeloop. Diabeloop Unveils New DBLG2 Demo App (30 June 2026; product-status section says DBLG2 is available with Kaleido and soon with Dana-i). https://www.diabeloop.com/news/company/dblg2-demo-app-en ↩

12. U.S. FDA. 510(k) K251152 — DBLG2 interoperable automated glycemic controller (decision 19 December 2025). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251152 ↩

13. Diabeloop and Sequel Med Tech. Partnership to integrate FDA-cleared DBLG2 into the twiist AID system (14 January 2026; target readiness end-2026, US launch 2027). https://www.diabeloop.com/media-press/press-releases/dbl-sequel-pr-en ↩